The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 1 of the 29 sources its claims cite were checked for support.
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC
Open accessPublished version of a preprint
Abstract
Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described. Experimental Design: Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients. Results: In the 118 patients treated with osimertinib, 42 had molecular profiling at progression. T790M was preserved in 21 (50%) patients and lost in 21 (50%). EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases. MET amplification was the second most common alteration (14%). Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET. Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers. Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01). In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months. Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02). Conclusions: Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. See related commentary by Devarakonda and Govindan, p. 6112.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Own result · 15 Not checked yet · 12 Own interpretation · 6 Own method · 2 No basis given · 1 Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These previously defined osimertinib-resistant EGFR mutations were exclusively observed in T790M-preserved cases; this association was statistically significant (11/19 vs. 0/21, p<0.001, Fisher exact test”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median PFS2 was 12.6 months (95% CI, 8.3 to 15.5, Supple. Fig. 5)”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Subsequent treatment post-progression on osimertinib
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In the T790M-preserved group, previously defined osimertinib-resistant EGFR mutations (11/19; C797S: 8; C797G: 1; L792H: 2 [20] [21]) were the most common resistance mechanisms.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
What the sources say
- Not checked yetcites [20] Ercan, 2015, EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors, Clin Cancer Res source
- Not checked yetcites [21] Chen, 2017, Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC, J Thorac Oncol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the osimertinib-continued patients, 21 (45%) received palliative radiation for oligometastatic progressing lesions”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Subsequent treatment post-progression on osimertinib
plainn = 21- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median PFS1 was 8.4 months (95%CI, 6.7 to 10.7, Fig. 1A)”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Patient characteristics and efficacy of osimertinib
plainn = 118- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that PIK3CA E545K overexpression confers moderate resistance to osimertinib (IC50 increased from 25nM to 67nM, p<0.01)”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CNS metastasis prior to osimertinib was associated with inferior outcome (PFS1 10.4 vs 4.6 months; HR 1.9, 95% CI, 1.2 – 3.0, log-rank p=0.01”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Patient characteristics and efficacy of osimertinib
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“OS Dx for the entire cohort was 71.9 months (95% CI 51.4 – 92.1”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Subsequent treatment post-progression on osimertinib
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median OS1 was 25.2 months (95% CI, 17.5 to 29.2, Supple. Fig. 2)”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Patient characteristics and efficacy of osimertinib
plainn = 118- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was a trend for improved outcomes in the radiated population compared to non-radiated patients (PFS2 15.5 vs 8.2 months; HR 0.5; 95% CI 0.3 to 1.0, log-rank p=0.05”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Subsequent treatment post-progression on osimertinib
hedgedcorrelationaln = 21 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 26
Every source the paper cites for this claim was checked and supports it.
In the paper
“Epithelial‐mesenchymal transition (EMT) has also been indicated as one mechanism of resistance to EGFR-TKIs[10].”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
What the sources say
- Supportedcites [10] Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med source
The Results section reports EMT-consistent changes in resistant tumors, including two cases with acquired vimentin expression and lost E-cadherin expression. The Discussion says the authors observed EMT in two cases of acquired EGFR-TKI resistance and in a cell line rendered resistant in vitro. This supports the claim's cautious wording, although the paper says the molecular connection remains unknown; page numbers are not available in the supplied copy. (LLM, conf=0.92)
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In HCC827 cells, norepinephrine (10uM) significantly increased proliferation in the presence of osimertinib (from 10–50nM), suggesting resistance (red line, Fig. 3F). Propranolol (1uM), a non-selective beta-adrenergic blocker, restored osimertinib sensitivity in HCC827 cells (gray line, Fig. 3F)”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the acquired T790M cases, 47% (19/40) preserved and 53% (21/40) lost T790M at progression”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 18 cases, 9 (50%) preserved T790M with 6 acquired EGFR C797S/L792H mutations”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition (EMT) as potential resistance drivers.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Abstract > Results:
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We cultured HCC827 cells (EGFR Del745_760) in erlotinib to develop EGFR TKI resistance and identified one clone (ER2) having increased c-Met protein expression and MET copy-number gain (Fig. 3A-3B). This clone was resistant to osimertinib (Supple. Fig. 7A) without resistant mutations in the EGFR exon 20 (Supple. Fig 7C), but exquisitely sensitive to c-met inhibitors”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas TP53 mutation and T790M loss were not (Supple. Fig. 4)”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Patient characteristics and efficacy of osimertinib
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
What the sources say
- Not checked yetcites [8] Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science source
- Not checked yetcites [23] Ou, 2016, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression, Lung Cancer source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“T790M was preserved in 21 (50%) patients and lost in 21 (50%).”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Abstract > Results:
plainn = 42- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three patients developed treatment-related pneumonitis and two patients developed treatment-related cardiotoxicity with decreased ejection.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Patient characteristics and efficacy of osimertinib
plaindirectn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our preclinical models, PIK3CA hotspot mutation, but not BRAF, FGFR, and PDGFR overexpression alone, was found to contribute to osimertinib resistance.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that epinephrine reduces the sensitivity of EGFR mutant cells to osimertinib in vitro. Beta-adrenergic blockade with propranolol reversed this resistance phenotype.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median follow-up on osimertinib was 13 months, with 63% alive at the time of analysis.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Patient characteristics and efficacy of osimertinib
plainn = 118- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“one had FGFR3/FGFR19 amplification (Pt. 32, Supple Table 2), one had MET amplification (Pt. 36; FISH ratio: 7.4, Supple Table 2) and one had ERBB2 amplification (Pt. 40, Supple Table 2).”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among MET-amplified patients, CDK6 (4/5) and BRAF amplification (3/5) were common events”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were 14 cases without potential resistance genetic drivers, 12 in T790M-preserved group”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This data suggests that acquired PIK3CA hotspot mutations may drive contribute to osimertinib resistance, and that BRAF, FGFR, or PDGFR amplifications may be “passenger” events instead of “drivers”, or may not be able to promote resistance alone without additional concurrent alterations.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
hedgedconditionaln = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“supporting that stress hormones induce proliferation in the presence of osimertinib. Furthermore, such resistance can be overcome through beta-adrenergic blockade in EGFR-mutant T790M-negative lung cancer cells.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Preclinical cell line findings translate to clinical osimertinib resistance in patients.
In the paper
“In a randomized phase III trial[3], osimertinib significantly improved both progression-free survival (PFS) and objective response rate (ORR) when compared to platinum-pemetrexed chemotherapy for T790M-positive non-small cell lung cancer (NSCLC) after progression on 1st or 2nd generation EGFR-TKIs.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > INTRODUCTION:
What the sources say
- Not checked yetcites [3] Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Written informed consents were obtained the patients, and the studies were conducted in accordance with ethical guidelines including Declaration of Helsinki and U.S. Common Rule. The study was approved by the IRBs at MDACC and University of South Florida.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > PATIENTS AND METHODS: > Study population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“We observed an AXL mutation in one case with acquired T790M/C797S (Pt. 12 Supple Table 2)[24], suggesting association with EMT.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
What the sources say
- Not checked yetcites [24] Zhang, 2012, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer, Nat Genet source
hedgedcorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We showed that many patients with EGFR-mutant NSCLC might have prolonged benefit from osimertinib beyond their initial progression event, especially when radiation was used at progression, suggesting a potential role for local consolidative therapy in this setting.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we showed that T790M loss is common in osimertinib-resistant cases, and that these cases demonstrated a different pattern of resistance compared with the T790M-preserved cases.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“when compared to erlotinib or gefitinib in the first-line setting for EGFR mutant NSCLC, osimertinib showed a significant PFS benefit in favor of osimertinib in a phase III study (FLAURA trial, NCT02296125) [4].”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > INTRODUCTION:
What the sources say
- Not checked yetcites [4] Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In the clinical outcome analysis, the disease progression was based on physician assessment and not specific formal criteria.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Reports on individual cases or clinical series have demonstrated that EGFR exon 20 tertiary mutations, including C797S[5–7], MET amplification[8], HER2 amplification[9], small cell transformation[10], and epithelial-mesenchymal transition (EMT) [10, 11] are possible drivers of resistance.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > INTRODUCTION:
What the sources say
- Not checked yetcites [5] Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med source
- Not checked yetcites [6] Yang, 2018, Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients, Clin Cancer Res source
- Not checked yetcites [7] Oxnard, 2018, Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib, JAMA Oncol source
- Not checked yetcites [8] Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science source
- Not checked yetcites [9] Takezawa, 2012, HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation, Cancer Discov source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because of the relative proximity of the three genes in chromosome 7q (CDK6 at Chr7q21.2, MET at Chr7q31.2 BRAF at Chr7q34), it is possible that these amplifications arose from a single genomic event.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In the genetic profiling analysis, in some cases different platforms were used for the pre-treatment and post-progression profiling; however, analysis of the platform-matched cases shows similar results as the overall analysis.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the majority of the patients in our cohort received osimertinib as second- or later-lines of therapy (Table 1), with only six patients with baseline EGFR T790M or germline T790M receiving osimertinib as the first-line treatment”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specifically, in most of the T790M-preserved cases, resistance is associated with continued EGFR activation through known resistance tertiary mutations (e.g. C797S) or activation of bypass signaling pathways, whereas resistance in T790M-loss cases occurs through diverse, and predominantly EGFR-independent mechanisms.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Stress hormone induced beta adrenergic pathway activation has recently been identified as a driver of resistance to first-generation TKIs and can be overcome by beta-adrenergic blockade[25]”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
What the sources say
- Not checked yetcites [25] Nilsson, 2017, Stress hormones promote EGFR inhibitor resistance in NSCLC: implications for combinations with beta-blockers, Sci Transl Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Both T790M-preserved and -loss groups had similar frequency with next-generation sequencing based paneled tests (14/19 vs. 15/21, Chi-Square p=0.87).”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
plainn = 42- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The molecular alterations detected in the 42 profiled patients are representative of resistance mechanisms in the broader osimertinib-treated cohort.
“Genomic profiling at the time of progression was available for 42 patients”
“The 18 platform-matched cases represent the common resistance mechanisms seen in our 42 cases cohort”
The paper relies on this without support.
Preclinical cell line findings translate to clinical osimertinib resistance in patients.
“Taken together, these preclinical data provide evidence that EGFR-independent mechanisms of resistance observed for first- and second-generation EGFR TKIs (MET amplification, PIK3CA mutation, EMT, beta adrenergic activation) may promote osimertinib resistance as well.”
The paper relies on this without support.
The historical median OS of 19–28 months with first- or second-generation EGFR TKIs is a valid comparator for this cohort's OS from diagnosis.
“a strikingly long survival compared to median OS of 19–28 months with first- or second-generation EGFR TKIs[17–19].”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“T790M-like-3R mutants, complex mutations comprising T790M and a known drug-resistance mutation (that is, C797S30, L718X31 or L792H18,31), were resistant to classical EGFR TKIs but retained selectivity for select ALK and PKC inhibitors such as brigatinib or midostaurin (Extended Data Fig. 7c).”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [18]
In the citing paper
“EGFR mutations were determined from formalin-fixed paraffin-embedded tumours or digital-droplet PCR for blood samples by CLIA-certified methods as previously described18,37.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
“There were 14 cases without potential resistance genetic drivers, 12 in T790M-preserved group, which highlights our limited understanding of T790M-negative resistance mechanisms.”
§ Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC > RESULTS > Potential mechanisms of resistance to osimertinib
“In the T790M-preserved group, previously defined osimertinib-resistant EGFR mutations (11/19; C797S: 8; C797G: 1; L792H: 2 [20] [21]) were the most common resistance mechanisms.”
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Research works printed but not linked: 1
- Oxnard, 2017, Osimertinib resistance mediated by loss of EGFR T790M is associated with early resistance and competing resistance mechanisms, S1767
Cited by
Sorted by citations
Items 301–388 of 388
Li, C., Nguyen, T. T., Lǐ, J., Song, X., Fujimoto, J., Little, L., Gumb, C., Chow, C.-W. B., Wistuba, I. I., Futreal, P. A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00680-0 · Cited by 4
Self-citationDou, Y., Liu, Y., Han, R., Zheng, J., Wang, L., Hu, C., Huang, D., He, C., Zhang, Y., Lin, C., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404087 · Cited by 4
Liu, R., Zhou, J., & Ling, X. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221103215 · Cited by 4
Shao, Y., Zhang, J., Feng, Z., Wu, W., Zhao, X., Zhu, M., Xiao, Y., Pang, J., Zhu, J., Qu, H., et al. (2024) · Cancer Science · doi:10.1111/cas.16250 · Cited by 3
Self-citationGhosh, M., Wu, C., Kumar, A., Nilsson, M. B., Heymach, J. V., Zhao, W., Yu, J., Liu, X., Ding, N., Wang, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198418 · Cited by 3
Self-citationQin, K., Wang, K., Li, S., Hong, L., Padmakumar, P., Rinsurongkawong, W., Hubert, S. M., Le, X., Vokes, N. I., Rai, K., et al. (2024) · Cancers · doi:10.3390/cancers16050935 · Cited by 4
Self-citationAssociation of PI3K/AKT/mTOR Pathway with Cancer and Its Therapeutic Implications
Saleem, S., Bashir, I., Khan, M. S., & Ahanger, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_3 · Cited by 3
Makimoto, G., Ohashi, K., Senoo, S., Hotta, K., Maeda, Y., & Kiura, K. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2152-18 · Cited by 3
Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs
Franceschini, D., Rossi, S., Loi, M., Chiola, I., Piccoli, F., Lutman, R. F., Finocchiaro, G., Toschi, L., Santoro, A., & Scorsetti, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1806716 · Cited by 3
Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
Iacovino, M. L., Ciaramella, V., Paragliola, F., Suarato, G., Busiello, G., & Sparano, F. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00024 · Cited by 3
Chen, J., Zhao, X., Wang, J., Liu, F., Zhang, L., Chen, Y., & Chu, Q. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-510 · Cited by 3
Li, M., Lin, C., Lin, J., Chen, S., Weng, L., & He, Z. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230803142758 · Cited by 3
Yamaguchi, T., Masago, K., Sasaki, E., Kuroda, H., Matsushita, H., & Horio, Y. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.12.001 · Cited by 4
Guo, L., Zhou, G., Huang, M., Tang, K., Xu, J., & Chen, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13748 · Cited by 2
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy
Ogusu, S., Ariyasu, R., Akita, T., Kiritani, A., Tsugitomi, R., Amino, Y., Uchibori, K., Kitazono, S., Yanagitani, N., & Nishio, M. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01301-y · Cited by 3
Zhang, L., Chinnam, M., Balk, B., Zhang, X., Wang, Y., Shaurova, T., Alam, S., Pokharel, S., Singh, P., Jacobi, J. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.668485 · Cited by 3
Ghafoor, A., Roper, N., Kim, C., Hoang, C. D., Kesarwala, A. H., Camphausen, K. A., Farouq, K., Akoth, E., Keen, C., Szabo, E. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100886 · Cited by 2
Liu, M., Gao, P., Liu, F., Li, D., Wang, Y., & Yu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1767999 · Cited by 2
Wang, Z., Song, Y., Wang, A., & 刘宝山 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1795614 · Cited by 2
Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines
Ulmer, B., Odenthal, M., Buettner, R., Roth, W., & Kloth, M. T. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00211-8 · Cited by 2
Moiseenko, F. V., Bogdanov, A. A., Egorenkov, V. V., Волков, Н. М., & Moiseyenko, V. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01019-2 · Cited by 2
MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing
To, K. K. W., Leung, K., & Cho, W. C. S. (2023) · Drugs and Drug Candidates · doi:10.3390/ddc2030031 · Cited by 2
PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC
Vokes, N. I., Le, X., & Yap, T. A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1188 · Cited by 2
Self-citationYang, W., Shi, L., Wang, H., Li, Y., Ji, X., Li, H., Yang, G., & Xu, W.-R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1481244 · Cited by 3
Blaquier, J. B., & Recondo, G. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2067705 · Cited by 2
Tone, M., Inomata, M., Awano, N., Kuse, N., Jo, T., Yoshimura, H., Minami, J., Takada, K., Miyamoto, S., & Izumo, T. (2020) · Anticancer Research · doi:10.21873/anticanres.14186 · Cited by 2
Takigawa, N., Ochi, N., & Yamane, H. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.11.01 · Cited by 2
Pérez, A. R., Felip, E., Chicas-Sett, R., Montero-Luis, Á., Arias, L. D. P., del Alba, A. G., López‐Campos, F., López, C., Hernando, O., Conde-Moreno, A. J., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03011-6 · Cited by 1
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
Spagnuolo, A., & Gridelli, C. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2464903 · Cited by 1
Qi, H., Qiao, Q., Sun, X., & Xing, L. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70085 · Cited by 1
Yao, H., Cao, L., Enzhuo, E., Yang, K., Ren, Y., Hou, P., Yan, M., & Li, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118120 · Cited by 1
Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer
Yue, M., Qin, Z., Tang, S., Cai, X., Zhao, Y., Yang, C., Chen, L., Chen, L., & Ji, H. (2025) · Nature Communications · doi:10.1038/s41467-025-67345-9 · Cited by 2
Hao, S., Yan, J.-H., Wang, R., Ge, G., Si, M.-C., Niu, Y.-F., Cai, Z.-H., Zheng, W., Zhao, C.-G., Li, X., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118637 · Cited by 1
Guo, J., Wen, Q., & Fan, S. (2026) · MedComm · doi:10.1002/mco2.70823 · Cited by 2
Sequencing Therapies in Oncogene-Driven Non-Small-Cell Lung Cancer: How to Get The Best Mileage?
Sukrithan, V., Snyder, R. B., Cheng, H., & Halmos, B. (2019) · Future Oncology · doi:10.2217/fon-2019-0103 · Cited by 1
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
Malapelle, U., & Passiglia, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104213 · Cited by 1
Romagnolo, A. P., Hino, C., Mirshahidi, S., Chase, K., & Mirshahidi, H. (2023) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2023.100232 · Cited by 1
AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells
Yu, H., Wang, Z., Dong, Y., Li, L., Fan, X., Zheng, N., Jiang, J., Lin, C., Lu, C., Li, K., et al. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j002 · Cited by 1
Giustini, N., Pritchard, C. C., Kamat, N. V., & Menon, M. P. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00215 · Cited by 1
Castellano, G. M., & Pine, S. R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.04.05 · Cited by 1
Yagihara, K., Hara, H., Ishii, J., Sumino, J., Katsurano, M., Shibata, M., Kim, Y., Haraguchi, M., & Ishikawa, A. (2021) · Journal of Japanese Society of Oral Oncology · doi:10.5843/jsot.33.195 · Cited by 1
EGFR-Directed Therapy in Lung Cancer
Kim, S. Y., Costa, D. B., Shibahara, D., Kobayashi, S. S., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009342285
Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC
Klempner, S. J., & Hata, A. N. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.014 · Cited by 1
Hydbring, P. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-117 · Cited by 1
Perspective: plasticity, the enemy of the good
Yvonnet, S., Barberousse, A., & Escargueil, A. E. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.23
Kinase inhibitors: look beyond the label on the bottle
Dent, P., Poklepovic, A. S., Booth, L. A., & Hancock, J. F. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.80
Physiologic and pathologic profiling of clonal variations
Wong, W. (2019) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/scfg-zs49
[Research Progress of New Generation EGFR-TKIs after Third-generation].
Liu, Y., Yihui, L. I., & Wang, J. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.28
Андреевна, К. А., & Феденко, А. А. (2020) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2020-19-6-119-125
Effect of Chemotherapy on Immune Factors in Patients with Non-Small Cell Lung Cancer
Zhang, J., Song, D., Dong, Y., Bai, L., Dongqi, G., Zhang, S., Guo, Y., Li, F., Yu, X., & Li, Q. (2021) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2021.912009
Self-citation(2019) · Reactions Weekly · doi:10.1007/s40278-019-57326-4
武, 卉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.127991
Dayanc, B., Eris, S., & Şentürk, Ş. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_54
[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].
Chen, R., Jiang, C., Tang, J., Ma, L., & Zhang, S. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.54
Epithelial-mesenchymal transition and resistance to EGFR inhibitors
Jacob, S., Kurupi, R., & Faber, A. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00009-7
Iyer, R. S., Needham, S. R., Galdadas, I., Davis, B. M., Roberts, S. K., Man, R. C. H., Zanetti-Domingues, L. C., Clarke, D. T., Fruhwirth, G. O., Parker, P. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.16.545259
Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancerPreprint
Yue, M., Qin, Z., Tang, S., Cai, X., Zhao, Y., Chen, L., Chen, L., & Ji, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.17.633515
Hsieh, M., Hung, T.-C., Huang, H., Lu, C.-W., Hu, H., Lai, J.-Y., Lee, W.-Y., & Chen, J. (2025) · Diagnostics · doi:10.3390/diagnostics15080948
Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients
Vingiani, A., Piccolo, A., Busico, A., Capone, I., Tamborini, E., Perrone, F., Marco, C. D., Verderio, P., Ciniselli, C. M., Proto, C., et al. (2026) · Tumori Journal · doi:10.1177/03008916261438383
Yang, S., Ngo, L. T., Lee, S., Yun, H., Bui, T. T., Kim, D.-H., Chae, J., & Park, S. (2025) · Pharmaceuticals · doi:10.3390/ph18050748
Qi, R., Chen, F., Liu, P., Gu, W., Shi, C., Zhang, G., & Qiu, F. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1615018
Li, W., Zhang, K., Raúl, M. L., Rotter-Maskowitz, A., Nejman, D., Potempa, J., Straussman, R., & Raz, D. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.08.681060
Oi, I., Fujita, K., Imakita, T., Okada, Y., Yoshimura, S., Fujimoto, N., Toyama, S., Watanabe, A., Ito, T., Kaku, R., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-15479-w
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933524
Han, R., Guo, H., Shi, J., Zhao, S., Jia, Y., Liu, X., Liu, Y., Cheng, L., Zhao, C., Li, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25687490
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933533
Han, R., Guo, H., Shi, J., Zhao, S., Jia, Y., Liu, X., Liu, Y., Cheng, L., Zhao, C., Li, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25687600
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933530
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933521
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933527
Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933518
Therapeutic Strategies for Overcoming Resistance to EGFR-TKIs Therapy in EGFR-Mutant NSCLC
苗, 霂. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161262
HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma
Li, H., Chen, Y., Wei, L., Wu, P., Fang, F., Li, F., Liu, B., Li, S., He, Q., Zhou, J., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109301
Une approche épistémologique du microenvironnement tumoral
Yvonnet, S. (2021) · theses.fr (ABES) · doi:10.70675/61f127c5z1568z4531zb1d9zde5b5223a474
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
Li, M., Xue, Y.-X., Chang, Y.-I., Xu, F., Wu, F., Tian, X.-J., Hu, J., Song, Y.-J., Yu, X.-F., Zhou, F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72062-y
Wang, L.-M., Yang, C., Chen, S., Sun, X., Tian, Y., Zhang, J., Gao, X., Li, D., Zhang, W., Hu, Y., et al. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag015
Self-citationNtzifa, A., Themistokli, E., Strati, A. D., Zavridou, M., Tsaroucha, E., Sfika, A., Psyrri, A., Balgouranidou, I., Kotsakis, A. P., Georgoulias, V., et al. (2026) · Cancers · doi:10.3390/cancers18111759
Tang, X., Zhu, Y., Yan, J., Wu, H., Chen, Y., Liu, Y., Tang, H., Wang, W., & Wang, Z. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.126
Alai, G., Li, L., Ma, G., Yong-sheng, Z., Yao, P., & Lin, Y.-D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1867246 · Cited by 1
Liu, Y., Tang, L., Han, X.-H., Song, Z.-Y., Liu, D.-R., Cheng, G., Xiao, W.-H., Zhang, S., Hu, Y., Zhang, L., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02994-w
Goldman, J. W., Riess, J. W., Cho, B. C., Goldberg, S. B., Le, X., Piotrowska, Z., Okamoto, I., Yu, H. A., Campelo, M. R. G., de Castro, J., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.09.001
Self-citationKnebel, F. H., Ribeiro, M. F. S. A., Linck, R. D. M., Ferreira, I. F., Masotti, C., Saddi, R., Sacardo, K. P., Canedo, F. S. N. A., Oliveira, L. J. D. C., Duarte, D. C., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72208
Hong, M. H., Shim, B. Y., Kim, C. G., Kim, Y. S., Lee, S., Lee, Y., Ahn, B., Ahn, M.-J., Ahn, J. S., Park, S., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117774
Zhang, K., Yu, X., Liu, Y., Zhang, H., Wang, X., Jiang, P., Li, X., Su, Y., Gao, Y., Chu, H., et al. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124739
Metadata
- Authors
- Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., Tang, M., Sun, H., Elamin, Y., Lacerda, L. C., Lewis, J., Roth, J. A., Swisher, S. G., Lee, J. J., William, W. N., Glisson, B. S., Zhang, J., Papadimitrakopoulou, V. A., Gray, J. E., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Gray, Jhanelle E.
- Heymach, John V.
- ORCID
- Le, Xiuning
- Puri, Sonam
- Negrao, Marcelo V.
- Nilsson, Monique B.
- Robichaux, Jacqulyne
- Boyle, Theresa
- Hicks, J. Kevin
- Lovinger, Katherine L.
- Rinsurongkawong, Waree
- Tang, Ming
- Sun, Huiying
- Elamin, Yasir
- Lewis, Jeff
- Roth, Jack A.
- Swisher, Stephen G.
- William, William N.
- Glisson, Bonnie S.
- Zhang, Jianjun
- Papadimitrakopoulou, Vassiliki A.
- Gray, Jhanelle E.
- Heymach, John V.
- Venue
- Clinical Cancer Research
- Published
- 2018-12-13
- Volume
- 24
- Issue
- 24
- Pages
- 6195-6203
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC6295279
- OpenAlex
- W2891909134
- Cited by
- 387
- References
- 34
- Citations by year
- 2026: 20 · 2025: 41 · 2024: 33 · 2023: 51 · 2022: 63 · 2021: 68 · 2020: 56 · 2019: 50 · 2018: 5
- FWCI
- 33.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- MD Anderson Cancer Center (P30 CA01667)
- NIH (R01 CA190628)
- UT Lung SPORE (P50 CA70907)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- osimertinib, EGFR-mutant non-small cell lung cancer, drug resistance mechanisms, T790M mutation, MET amplification, PIK3CA, fibroblast growth factor receptor, RET, epithelial-mesenchymal transition, cell cycle genes, progression-free survival, consolidation radiotherapy, overall survival
- MeSH terms
- Acrylamides, Adult, Aged, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Pyrimidines, Retrospective Studies, Survival Analysis, Treatment Outcome, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
